KALA Pharmaceuticals entered into a Securities Purchase Agreement to issue and sell Series F Convertible Non-Redeemable Preferred Stock for gross proceeds of $2.0 million in a private placement.
AI Assistant
KALA BIO INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.